Non-alcoholic fatty liver disease and cognitive impairment

Non-alcoholic fatty liver disease and cognitive impairment

Aim. To evaluate the efficacy of oral administration of the original ademetionine (Geptral) at a dose of 1500 mg/s in patients with NAFLD at the steatosis stage and cognitive impairment within the framework of a prospective observational open non-comparative study in real clinical practice against t...

Full description

Bibliographic Details
Main Authors: Elena V. Onuchina, Bairma B. Dambaeva, Anna G. Glazunova, Ayuna Kh. Mikhailova, Elena M. Vorobyova, Elena I. Soshina, Natalya V. Efremenko
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2024-12-01
Series:Терапевтический архив
Subjects:
nonalcoholic fatty liver disease
cognitive impairment
s-adenosylmethionine
Online Access:https://ter-arkhiv.ru/0040-3660/article/viewFile/656035/pdf

Internet

https://ter-arkhiv.ru/0040-3660/article/viewFile/656035/pdf

Similar Items